157 related articles for article (PubMed ID: 38330916)
1. Biosynthesis of Dolastatin 10 in Marine Cyanobacteria, a Prototype for Multiple Approved Cancer Drugs.
Kallifidas D; Dhakal D; Chen M; Chen QY; Kokkaliari S; Colon Rosa NA; Ratnayake R; Bruner SD; Paul VJ; Ding Y; Luesch H
Org Lett; 2024 Feb; 26(7):1321-1325. PubMed ID: 38330916
[TBL] [Abstract][Full Text] [Related]
2. Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides.
Harrigan GG; Luesch H; Yoshida WY; Moore RE; Nagle DG; Paul VJ; Mooberry SL; Corbett TH; Valeriote FA
J Nat Prod; 1998 Sep; 61(9):1075-7. PubMed ID: 9748368
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
Yokosaka S; Izawa A; Sakai C; Sakurada E; Morita Y; Nishio Y
Bioorg Med Chem; 2018 May; 26(8):1643-1652. PubMed ID: 29454703
[TBL] [Abstract][Full Text] [Related]
4. Dolastatin 15 from a Marine Cyanobacterium Suppresses HIF-1α Mediated Cancer Cell Viability and Vascularization.
Ratnayake R; Gunasekera SP; Ma JJ; Dang LH; Carney TJ; Paul VJ; Luesch H
Chembiochem; 2020 Aug; 21(16):2356-2366. PubMed ID: 32237262
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains.
Dugal-Tessier J; Barnscher SD; Kanai A; Mendelsohn BA
J Nat Prod; 2017 Sep; 80(9):2484-2491. PubMed ID: 28885014
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
Taori K; Liu Y; Paul VJ; Luesch H
Chembiochem; 2009 Jul; 10(10):1634-9. PubMed ID: 19514039
[TBL] [Abstract][Full Text] [Related]
7. Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.
Luesch H; Yoshida WY; Moore RE; Paul VJ; Mooberry SL; Corbett TH
J Nat Prod; 2002 Jan; 65(1):16-20. PubMed ID: 11809057
[TBL] [Abstract][Full Text] [Related]
8. Portobelamides A and B and Caciqueamide, Cytotoxic Peptidic Natural Products from a
Demirkiran O; Almaliti J; Leão T; Navarro G; Byrum T; Valeriote FA; Gerwick L; Gerwick WH
J Nat Prod; 2021 Aug; 84(8):2081-2093. PubMed ID: 34269583
[TBL] [Abstract][Full Text] [Related]
9. Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium Caldora penicillata.
Gunasekera SP; Imperial L; Garst C; Ratnayake R; Dang LH; Paul VJ; Luesch H
J Nat Prod; 2016 Jul; 79(7):1867-71. PubMed ID: 27380142
[TBL] [Abstract][Full Text] [Related]
10. Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp.
Taori K; Matthew S; Rocca JR; Paul VJ; Luesch H
J Nat Prod; 2007 Oct; 70(10):1593-600. PubMed ID: 17910513
[TBL] [Abstract][Full Text] [Related]
11. Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12.
Bai R; Covell DG; Taylor GF; Kepler JA; Copeland TD; Nguyen NY; Pettit GR; Hamel E
J Biol Chem; 2004 Jul; 279(29):30731-40. PubMed ID: 15123603
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
Pettit GR; Melody N; Chapuis JC
J Nat Prod; 2017 Mar; 80(3):692-698. PubMed ID: 28211277
[TBL] [Abstract][Full Text] [Related]
13. Somamides A and B, two new depsipeptide analogues of dolastatin 13 from a Fijian cyanobacterial assemblage of Lyngbya majuscula and Schizothrix species.
Nogle LM; Williamson RT; Gerwick WH
J Nat Prod; 2001 Jun; 64(6):716-9. PubMed ID: 11421730
[TBL] [Abstract][Full Text] [Related]
14. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.
Luesch H; Moore RE; Paul VJ; Mooberry SL; Corbett TH
J Nat Prod; 2001 Jul; 64(7):907-10. PubMed ID: 11473421
[TBL] [Abstract][Full Text] [Related]
15. Total synthesis and biological activity of dolastatin 16.
Casalme LO; Yamauchi A; Sato A; Petitbois JG; Nogata Y; Yoshimura E; Okino T; Umezawa T; Matsuda F
Org Biomol Chem; 2017 Feb; 15(5):1140-1150. PubMed ID: 28074955
[TBL] [Abstract][Full Text] [Related]
16. Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages.
Harrigan GG; Yoshida WY; Moore RE; Nagle DG; Park PU; Biggs J; Paul VJ; Mooberry SL; Corbett TH; Valeriote FA
J Nat Prod; 1998 Oct; 61(10):1221-5. PubMed ID: 9784156
[TBL] [Abstract][Full Text] [Related]
17. Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides.
Matthew S; Ross C; Rocca JR; Paul VJ; Luesch H
J Nat Prod; 2007 Jan; 70(1):124-7. PubMed ID: 17253864
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.
Singh SB
J Nat Prod; 2022 Mar; 85(3):666-687. PubMed ID: 35072477
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
20. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
